Tolerability and efficacy of BrECADD versus BEACOPP in advanced stage classical Hodgkin lymphoma: GHSG HD21, a randomized study.

person Peter Borchmann University Hospital of Cologne, and Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), and German Hodgkin Study Group (GHSG), Cologne, Germany info_outline Peter Borchmann, Alden A Moccia, Richard Greil, Gundolf Schneider, Mark Hertzberg, Valdete Schaub, Andreas Huettmann, Felix Keil, Judith Dierlamm, Mathias Haenel, Julia Meissner, Stephan Mathas, Josee M Zijlstra, Alexander Fosså, Justin Ferdinandus, Michael Fuchs, Wolfram Klapper, Hans-Theodor Eich, Carsten Kobe, Volker Diehl

Authors person Peter Borchmann University Hospital of Cologne, and Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), and German Hodgkin Study Group (GHSG), Cologne, Germany info_outline Peter Borchmann, Alden A Moccia, Richard Greil, Gundolf Schneider, Mark Hertzberg, Valdete Schaub, Andreas Huettmann, Felix Keil, Judith Dierlamm, Mathias Haenel, Julia Meissner, Stephan Mathas, Josee M Zijlstra, Alexander Fosså, Justin Ferdinandus, Michael Fuchs, Wolfram Klapper, Hans-Theodor Eich, Carsten Kobe, Volker Diehl Organizations University Hospital of Cologne, and Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), and German Hodgkin Study Group (GHSG), Cologne, Germany, Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland, Department of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectious Disease, Rheumatology, Oncologic Center, Laboratory for Immunological and Molecular Cancer Research, Paracelsus Medical University, Salzburg Cancer Research, Salzburg, Austria, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, and Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), and German Hodgkin Study Group (GHSG), Cologne, Germany, Prince of Wales Hospital, Department of Haematology, and Australasian Leukaemia & Lymphoma Group, Sidney, Australia, University of Tuebingen, Tuebingen, Germany, Department of Haematology, University Hospital, University Duisburg-Essen, Essen, Germany, Department of Haematology, Hanusch Krankenhaus, Vienna, Austria, University Hospital Hamburg-Eppendorf, Hamburg, Germany, Department III of Internal Medicine, University Hospital Chemnitz, Chemnitz, Germany, Department of Hematology and Oncology, University of Heidelberg, Heidelberg, Germany, Charité - Universitätsmedizin Berlin, Hematology, Oncology and Tumor Immunology, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, VU University Medical Center, Amsterdam, Netherlands, Department of Oncology, Oslo University Hospital, Oslo, Norway and Nordic Lymphoma Group, Oslo, Norway, Department of Pathology, Division of Hematopathology and Lymph Node Registry, Schleswig-Holstein Medical Center, Campus Kiel, Kiel, Germany, Department of Radiotherapy, University Hospital of Muenster, Münster, Germany, Department of Nuclear Medicine, University Hospital of Cologne, Cologne, and Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), and German Hodgkin Study Group (GHSG), Cologne, Germany Abstract Disclosures

Clinical